RecruitingPhase 2NCT05554393
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
Sponsor: National Cancer Institute (NCI)
Allentown, PA · Danville, PA · Hershey, PA · +172 more sites